Inhibikase Therapeutics Inc（IKT）の株式分析IKTInhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.